Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059485 · ClinicalTrials.gov registry record · Phase 2
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
A Phase 2 study of Acute Myelogenous Leukemia, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 4
- Study locations
NCT03059485: Active Phase 2 study of Acute Myelogenous Leukemia, sponsored by Beth Israel Deaconess Medical Center.
NCT03059485 is a Phase 2 study of Acute Myelogenous Leukemia that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 82 participants, below the 138-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (41% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03059485, a Phase 2 study of Acute Myelogenous Leukemia, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Conditions Studied
Interventions
- OTHER Observation
- BIOLOGICAL DC/AML Fusion Vaccine
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2026-12-04 |
| Phase | Phase 2 |
What the registry record for NCT03059485 still lists
NCT03059485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 138-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.
NCT03059485 reports a single indexed study location in Massachusetts, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03059485 about?
NCT03059485 is a clinical study titled "DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission". This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
What is the current status of trial NCT03059485?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2017-06-01. Estimated completion is 2026-12-04.
What conditions does trial NCT03059485 study?
This clinical trial studies the following conditions: Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT03059485?
The interventions under investigation include: Observation (OTHER), DC/AML Fusion Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03059485?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03059485 being conducted?
This trial has 4 study locations across Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03059485's enrollment target sits among peer trials
82 12th of 38 higher than 27 of 38 other Acute Myelogenous Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myelogenous Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
COMPLETED · Phase 2
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI